Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 11/20 | 0.53 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22004373 | 0.86 | ACLY (0.52) | ACLY | |
| SCHEMBL22004165 | 0.85 | ACLY (0.55) | ACLYF2RL3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL22004376 | 0.82 | ACLY (0.52) | ACLYCYP3A4MAPTTHRB | |
| SCHEMBL22021598 | 0.82 | ACLY (0.53) | ACLYF2RL3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL22004330 | 0.80 | ACLY (0.50) | ACLYMAPTTHRB | |
| SCHEMBL22004334 | 0.77 | ACLY (0.51) | ACLYCYP1A2CYP3A4MAPTTHRB | |
| SCHEMBL22004313 | 0.77 | ACLY (0.47) | ACLYCYP1A2CYP3A4MAPTTHRB | |
| SCHEMBL22004326 | 0.73 | ACLY (0.47) | ACLYMAPTTHRB | |
| SCHEMBL22004122 | 0.73 | ACLY (0.46) | ACLYMAPTTHRB | |
| SCHEMBL22003798 | 0.71 | ACLY (0.44) | ACLYMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885F2RL3 4563/4885CYP1A2 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.